A clutch of South Korean biopharmaceutical companies plan to go public this year, raising capital to expand production capacity as the country strives to become a global powerhouse for the manufacture of biopharmaceutical products.
The batch of newcomers could reshape the pharmaceuticals sector they are bigger than most existing listed players and will potentially add liquidity and attract more foreign investment to one of the hottest sectors in the Korean market.
The moves reflect a strong demand for quality healthcare assets and favourable IPO rules. Yet the political scandal gripping the country could yet impact this promising growth story.
First out of the blocks...